XOMA Royalty Corporation (NASDAQ:XOMA) — Market Cap & Net Worth
Market Cap & Net Worth: XOMA Royalty Corporation (XOMA)
XOMA Royalty Corporation (NASDAQ:XOMA) has a market capitalization of $710.16 Million ($710.16 Million) as of August 25, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10564 globally and #2810 in its home market, demonstrating a -8.39% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying XOMA Royalty Corporation's stock price $40.17 by its total outstanding shares 17678742 (17.68 Million). Check XOMA Royalty Corporation (XOMA) share price today for real-time trading data and today's change.
XOMA Royalty Corporation Market Cap History: 2015 to 2026
XOMA Royalty Corporation's market capitalization history from 2015 to 2026. Data shows growth from $470.25 Million to $710.16 Million (6.22% CAGR).
Index Memberships
XOMA Royalty Corporation is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.63 Trillion | 0.03% | #299 of 976 |
|
NASDAQ Composite
IXIC
|
$41.42 Trillion | 0.00% | #1097 of 3165 |
Weight: XOMA Royalty Corporation's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
XOMA Royalty Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how XOMA Royalty Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check XOMA book value to evaluate the company's book value and shareholders' equity.
Latest Price to Sales (P/S) Ratio
9.01x
XOMA Royalty Corporation's market cap is 9.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
14.82x
XOMA Royalty Corporation's market cap is 14.82 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $74.60 Million | $5.56 Million | -$53.53 Million | 13.41x | N/A |
| 2017 | $629.36 Million | $52.69 Million | $14.60 Million | 11.94x | 43.12x |
| 2018 | $223.64 Million | $5.30 Million | -$13.34 Million | 42.20x | N/A |
| 2019 | $482.63 Million | $18.37 Million | -$1.98 Million | 26.27x | N/A |
| 2020 | $780.16 Million | $29.39 Million | $13.30 Million | 26.55x | 58.67x |
| 2021 | $368.60 Million | $38.16 Million | $15.80 Million | 9.66x | 23.33x |
| 2022 | $325.29 Million | $6.03 Million | -$17.10 Million | 53.97x | N/A |
| 2023 | $327.06 Million | $4.76 Million | -$40.83 Million | 68.74x | N/A |
| 2024 | $464.60 Million | $28.49 Million | -$13.82 Million | 16.31x | N/A |
| 2025 | $470.08 Million | $52.15 Million | $31.71 Million | 9.01x | 14.82x |
Competitor Companies of XOMA by Market Capitalization
Companies near XOMA Royalty Corporation in the global market cap rankings as of August 25, 2026. Also see XOMA operating cash flow for how efficiently the company converts equity into cash flow.
Key companies related to XOMA Royalty Corporation by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #188 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #323 globally with a market cap of $83.19 Billion USD.
- CSL Ltd (AU:CSL): Ranked #475 globally with a market cap of $57.77 Billion USD ( AU$81.65 Billion AUD).
- Samsung Biologics Co Ltd (KO:207940): Ranked #564 globally with a market cap of $48.66 Billion USD ( ₩71.80 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #188 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $548.05 |
| #323 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $83.19 Billion | $834.04 |
| #475 | CSL Ltd | AU:CSL | $57.77 Billion | AU$168.30 |
| #564 | Samsung Biologics Co Ltd | KO:207940 | $48.66 Billion | ₩1551000.00 |
XOMA Royalty Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, XOMA Royalty Corporation's market cap moved from $470.25 Million to $ 710.16 Million, with a yearly change of 6.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $710.16 Million | +51.07% |
| 2025 | $470.08 Million | +1.18% |
| 2024 | $464.60 Million | +42.05% |
| 2023 | $327.06 Million | +0.54% |
| 2022 | $325.29 Million | -11.75% |
| 2021 | $368.60 Million | -52.75% |
| 2020 | $780.16 Million | +61.65% |
| 2019 | $482.63 Million | +115.81% |
| 2018 | $223.64 Million | -64.47% |
| 2017 | $629.36 Million | +743.60% |
| 2016 | $74.60 Million | -84.14% |
| 2015 | $470.25 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 24th, 2026 the market cap of XOMA Royalty Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $710.16 Million USD |
| MoneyControl | $710.16 Million USD |
| MarketWatch | $710.16 Million USD |
| marketcap.company | $710.16 Million USD |
| Reuters | $710.16 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About XOMA Royalty Corporation
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with co… Read more